Jump Financial’s enGene Therapeutics ENGN Stock Holding History
Bought
Maintained
Sold
Other funds holding ENGN
FIS
PA
SL
VA
BOCH
DTC
B
NI
VPC
MB
Jump Financial's ENGN Position: Q1 2026 in Review
Jump Financial increased its enGene Therapeutics (ENGN) stake by 61% in Q1 2026, buying an estimated $73.3K and bringing the position to 21,633 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1718.
Jump Financial first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.
- Jump Financial held 21,633 shares of enGene Therapeutics worth $147K as of Q1 2026.
- Jump Financial bought 8,233 enGene Therapeutics shares in Q1 2026, an estimated $73.3K.
- enGene Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q1 2026, its #1718 holding.
- Jump Financial first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
- 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.
Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.